Omecamtiv mecarbil enhances the duty ratio of human β-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle

Anja M. Swenson, X. Wanjian Tang, Cheavar A. Blair, Christopher M. Fetrow, William C. Unrath, Michael J. Previs, Kenneth S. Campbell, Christopher M. Yengo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The small molecule drug omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear. We expressed and purified human β-cardiac myosin subfragment 1 (M2β-S1) containing a C-terminal Avi tag. We demonstrate that the maximum actin-activated ATPase activity of M2β-S1 is slowed more than 4-fold in the presence of OM, whereas the actin concentration required for halfmaximal ATPase was reduced dramatically (30-fold).WefindOM does not change the overall actin affinity. Transient kinetic experiments suggest that there are two kinetic pathways in the presence ofOM.The dominant pathway results in a slow transition between actomyosinADP states and increases the time myosin is strongly bound to actin. However, OM also traps a population of myosin heads in a weak actin affinity state with slow product release. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay. The ionic strength dependence of in vitro motility suggests the inhibition may be at least partially due to drag forces from weakly attached myosin heads.OMcausesanincrease in duty ratioexaminedin the motility assay. Experiments with permeabilized human myocardium demonstrate that OM increases calcium sensitivity and slows force development (ktr) in a concentration-dependent manner, whereas the maximally activated force is unchanged. We propose thatOM increases the myosin duty ratio, which results in enhanced calcium sensitivity but slower force development in human myocardium.

Original languageEnglish (US)
Pages (from-to)3768-3778
Number of pages11
JournalJournal of Biological Chemistry
Volume292
Issue number9
DOIs
StatePublished - Mar 3 2017

Fingerprint

Cardiac Myosins
Myosins
Muscle
Actins
Myocardium
Calcium
Assays
Myosin Subfragments
Kinetics
Human Development
Ionic strength
Osmolar Concentration
Drag
Adenosine Triphosphatases
Experiments
omecamtiv mecarbil
Molecules
Pharmaceutical Preparations
Population

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Swenson, Anja M. ; Tang, X. Wanjian ; Blair, Cheavar A. ; Fetrow, Christopher M. ; Unrath, William C. ; Previs, Michael J. ; Campbell, Kenneth S. ; Yengo, Christopher M. / Omecamtiv mecarbil enhances the duty ratio of human β-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle. In: Journal of Biological Chemistry. 2017 ; Vol. 292, No. 9. pp. 3768-3778.
@article{2adabebb083148f58492d4aec8260a8a,
title = "Omecamtiv mecarbil enhances the duty ratio of human β-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle",
abstract = "The small molecule drug omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear. We expressed and purified human β-cardiac myosin subfragment 1 (M2β-S1) containing a C-terminal Avi tag. We demonstrate that the maximum actin-activated ATPase activity of M2β-S1 is slowed more than 4-fold in the presence of OM, whereas the actin concentration required for halfmaximal ATPase was reduced dramatically (30-fold).WefindOM does not change the overall actin affinity. Transient kinetic experiments suggest that there are two kinetic pathways in the presence ofOM.The dominant pathway results in a slow transition between actomyosinADP states and increases the time myosin is strongly bound to actin. However, OM also traps a population of myosin heads in a weak actin affinity state with slow product release. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay. The ionic strength dependence of in vitro motility suggests the inhibition may be at least partially due to drag forces from weakly attached myosin heads.OMcausesanincrease in duty ratioexaminedin the motility assay. Experiments with permeabilized human myocardium demonstrate that OM increases calcium sensitivity and slows force development (ktr) in a concentration-dependent manner, whereas the maximally activated force is unchanged. We propose thatOM increases the myosin duty ratio, which results in enhanced calcium sensitivity but slower force development in human myocardium.",
author = "Swenson, {Anja M.} and Tang, {X. Wanjian} and Blair, {Cheavar A.} and Fetrow, {Christopher M.} and Unrath, {William C.} and Previs, {Michael J.} and Campbell, {Kenneth S.} and Yengo, {Christopher M.}",
year = "2017",
month = "3",
day = "3",
doi = "10.1074/jbc.M116.748780",
language = "English (US)",
volume = "292",
pages = "3768--3778",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "9",

}

Omecamtiv mecarbil enhances the duty ratio of human β-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle. / Swenson, Anja M.; Tang, X. Wanjian; Blair, Cheavar A.; Fetrow, Christopher M.; Unrath, William C.; Previs, Michael J.; Campbell, Kenneth S.; Yengo, Christopher M.

In: Journal of Biological Chemistry, Vol. 292, No. 9, 03.03.2017, p. 3768-3778.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Omecamtiv mecarbil enhances the duty ratio of human β-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle

AU - Swenson, Anja M.

AU - Tang, X. Wanjian

AU - Blair, Cheavar A.

AU - Fetrow, Christopher M.

AU - Unrath, William C.

AU - Previs, Michael J.

AU - Campbell, Kenneth S.

AU - Yengo, Christopher M.

PY - 2017/3/3

Y1 - 2017/3/3

N2 - The small molecule drug omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear. We expressed and purified human β-cardiac myosin subfragment 1 (M2β-S1) containing a C-terminal Avi tag. We demonstrate that the maximum actin-activated ATPase activity of M2β-S1 is slowed more than 4-fold in the presence of OM, whereas the actin concentration required for halfmaximal ATPase was reduced dramatically (30-fold).WefindOM does not change the overall actin affinity. Transient kinetic experiments suggest that there are two kinetic pathways in the presence ofOM.The dominant pathway results in a slow transition between actomyosinADP states and increases the time myosin is strongly bound to actin. However, OM also traps a population of myosin heads in a weak actin affinity state with slow product release. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay. The ionic strength dependence of in vitro motility suggests the inhibition may be at least partially due to drag forces from weakly attached myosin heads.OMcausesanincrease in duty ratioexaminedin the motility assay. Experiments with permeabilized human myocardium demonstrate that OM increases calcium sensitivity and slows force development (ktr) in a concentration-dependent manner, whereas the maximally activated force is unchanged. We propose thatOM increases the myosin duty ratio, which results in enhanced calcium sensitivity but slower force development in human myocardium.

AB - The small molecule drug omecamtiv mecarbil (OM) specifically targets cardiac muscle myosin and is known to enhance cardiac muscle performance, yet its impact on human cardiac myosin motor function is unclear. We expressed and purified human β-cardiac myosin subfragment 1 (M2β-S1) containing a C-terminal Avi tag. We demonstrate that the maximum actin-activated ATPase activity of M2β-S1 is slowed more than 4-fold in the presence of OM, whereas the actin concentration required for halfmaximal ATPase was reduced dramatically (30-fold).WefindOM does not change the overall actin affinity. Transient kinetic experiments suggest that there are two kinetic pathways in the presence ofOM.The dominant pathway results in a slow transition between actomyosinADP states and increases the time myosin is strongly bound to actin. However, OM also traps a population of myosin heads in a weak actin affinity state with slow product release. We demonstrate that OM can reduce the actin sliding velocity more than 100-fold in the in vitro motility assay. The ionic strength dependence of in vitro motility suggests the inhibition may be at least partially due to drag forces from weakly attached myosin heads.OMcausesanincrease in duty ratioexaminedin the motility assay. Experiments with permeabilized human myocardium demonstrate that OM increases calcium sensitivity and slows force development (ktr) in a concentration-dependent manner, whereas the maximally activated force is unchanged. We propose thatOM increases the myosin duty ratio, which results in enhanced calcium sensitivity but slower force development in human myocardium.

UR - http://www.scopus.com/inward/record.url?scp=85014644427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014644427&partnerID=8YFLogxK

U2 - 10.1074/jbc.M116.748780

DO - 10.1074/jbc.M116.748780

M3 - Article

C2 - 28082673

AN - SCOPUS:85014644427

VL - 292

SP - 3768

EP - 3778

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 9

ER -